Convergence-sibling Calchan appoints former Pfizer man as CSO
This article was originally published in Scrip
Calchan, a small UK-based biotech company focused on the R&D of novel molecules targeting pain and inflammation, has appointed Zahid Ali as chief scientific officer. He joins from Pfizer where he was a senior director of clinical research. Calchan was formed at the same time as Convergence Pharmaceuticals (sold to Biogen recently in a deal worth up to $675m), also using ex-GSK assets. Calchan is being run by much of Convergence's old management team using funds that were carved out from money raised by Convergence prior to its sale. Its most advanced project is a Phase I/II asset, CNV2197944, which is a novel state-dependent calcium channel blocker (Cav2.2) with efficacy across a range of preclinical pain models. The company's second program is at a preclinical stage and targets the apoptosis signal-regulating kinase 1 (ASK1) which is implicated in pain, inflammation, ischemia, fibrosis, cancer and neurodegeneration. The program is partnered with Galapagos.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.